Matinas Biopharma Holdings - 48 Year Dividend Yield History | MTNB

Historical dividend payout and yield for Matinas Biopharma Holdings (MTNB) since 1971. The current TTM dividend payout for Matinas Biopharma Holdings (MTNB) as of March 22, 2019 is $0.00. The current dividend yield for Matinas Biopharma Holdings as of March 22, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.137B $0.000B
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $47.705B 31.73
Takeda Pharmaceutical (TAK) Japan $33.622B 12.44
Grifols (GRFS) Spain $13.132B 15.92
Mannatechorporated (MTEX) United States $0.044B 0.00